Prevalence and Distribution of High- and Low- Risk HPV Genotypes in Women Living in the Metropolitan Area of Naples: A Recent Update.
COVID-19
Cervical cancer
Prevention
Vaccines
human papillomavirus
Journal
Asian Pacific journal of cancer prevention : APJCP
ISSN: 2476-762X
Titre abrégé: Asian Pac J Cancer Prev
Pays: Thailand
ID NLM: 101130625
Informations de publication
Date de publication:
01 Feb 2023
01 Feb 2023
Historique:
received:
27
04
2022
entrez:
28
2
2023
pubmed:
1
3
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Human papillomavirus (HPV) can infect both male and female genitals, skin, and mucous membranes, causing benign or malignant lesions. HPV is a common sexually transmitted infection and it is the main cause of cervical cancer. The present retrospective study updated the previously published data on HPV genotypes distribution among women living in Naples. In this study, 502 cervical scrape specimens were collected from women with abnormal cytological indication and analyzed for HPV DNA identification by Linear Array HPV genotyping test. The HPV infection rate was 24.1%. HPV-16 (14.6%) was the most representative HR-HPV genotypes, followed by HPV-31 (13.8%), -18 (9.2%), and HPV-51 (8.5%). In addition, HPV-42 (16.4%) was the most prevalent genotype among LR-HPV genotypes (low-risk human papillomavirus). It was also found that women at the age group of 23-29 years (42.5%) were at the highest risk of HPV infection. It was found that the HPV-16 frequency decreased, but HPV-31 and -18 frequency increased a little. The LR HPV-53 frequency decreased, leaving the first place for abundance to the LR HPV-42. HPV-6 frequency did not change. LR HPV -11 was no more present. Merging <23 and 23-29 age classes into one class followed the same result. HPV prevalence declined in comparison to the previous data. A frequency variation was recorded for several genotypes in this study. Data can be useful to implement the preventative strategies and to promote HPV vaccination.
Identifiants
pubmed: 36853290
doi: 10.31557/APJCP.2023.24.2.435
pmc: PMC10162623
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
435-441Références
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
J Natl Cancer Inst. 1992 Mar 18;84(6):394-8
pubmed: 1311392
Virology. 2015 Feb;476:341-344
pubmed: 25577151
J Obstet Gynaecol. 2019 Jan;39(1):1-10
pubmed: 30370796
BMC Infect Dis. 2013 Aug 13;13:373
pubmed: 23941096
Expert Rev Vaccines. 2014 Nov;13(11):1279-90
pubmed: 25256262
Br J Cancer. 2003 Jan 13;88(1):63-73
pubmed: 12556961
Asian Pac J Cancer Prev. 2021 Jun 01;22(6):1843-1849
pubmed: 34181341
Viruses. 2020 Dec 24;13(1):
pubmed: 33374445
Dermatologica. 1981;162(4):213-9
pubmed: 6266889
J Natl Cancer Inst. 2010 Mar 3;102(5):325-39
pubmed: 20139221
Vaccine. 2006 Aug 31;24 Suppl 3:S3/1-10
pubmed: 16949995
Asian Pac J Cancer Prev. 2021 Sep 01;22(9):2969-2976
pubmed: 34582669
Lancet Oncol. 2010 Nov;11(11):1048-56
pubmed: 20952254
Virology. 2004 Jun 20;324(1):17-27
pubmed: 15183049
Cancer Epidemiol. 2019 Dec;63:101625
pubmed: 31704648
CA Cancer J Clin. 2020 Jul;70(4):274-280
pubmed: 32639044